The Disease Forecasting Company.
The world’s most trusted independent health intelligence, cited over 16,000 times in 2022
Analysis & Insights
Airfinity Named The Financial Times' Healthcare Tech Champion 2023
Airfinity has been selected as the winning company in the healthcare category of the FT’s 2023 Tech Champions. The awards recognise the tech companies that have risen to the challenges and opportunities presented by new global risks, economic headwinds, geopolitical crises, and disruptive AI.
Read More →
More from Airfinity
Airfinity named among Bloomberg’s UK Startups to Watch 2023
Airfinity appoints first Chief Medical Officer as part of increased pre-emptive health investments
France faces massive increase in dengue cases by 2030
Wegovy costs $1.1m to prevent one heart attack, stroke, or cardiovascular death
Climate change and vector-borne disease outbreaks: what you need to know
Elderly RSV vaccines to generate $10.5B annually by 2030 in G7 countries
View All →
In the News
Airfinity gives decision makers big picture on health
Financial Times | Nov 15, 2023
These Are the Top 25 UK Startups to Watch This Year
Bloomberg | Oct 24, 2023
Almost half the world’s population could be at risk from dengue due to global warming
The Telegraph | Oct 20, 2023
France faces massive increase in dengue cases by 2030
Politico | Oct 18, 2023
View All →
A pioneer in predictive health intelligence
Understand
What's happening in a given disease area?
Airfinity is the most comprehensive, single source of intelligence for new developments in your chosen area.
Predict
Identify the true need for a vaccine or a treatment.
Our suite of dynamic predictive indicators help you navigate highly dynamic and uncertain market developments and see the real opportunities.
Act
Maximise impact to save lives
Our analytics and probabilistic tools inform key decisions on resource allocation, investment and procurement decisions to maximise impact of a given drug or vaccine and ultimately improve as many lives as possible.
The world's most comprehensive infectious disease solutions.
Airfinity combines proprietary surveillance tools and forecast models with expert analysis for dozens of infectious diseases, including COVID-19, MPX, Influenza and RSV
OUR PLATFORM:
New science
Market & Production
Policies
Disease & Prevalence
What our users say?
“The Airfinity report is a guide for world leaders to fix a more ambitious action plan.”
Gordon Brown, WHO Ambassador for Global Health Financing & former UK Prime Minister
“Airfinity has been instrumental in our country's COVID response.”
Head of UK Government
Vaccine Task Force
“Vaccine production data from Airfinity has been spot on. In a fast moving pandemic, these forecasts are really important for evidence-based policy making.”
Director General,
IFPMA
“Airfinity has been critical in furnishing us and the rest of the world with COVID-19 numbers.”
James Fransham, Data Journalist,
The Economist